Literature DB >> 1342062

Treatment of malignant peritoneal effusion in digestive and ovarian cancer.

F N Gilly1, P Y Carry, A Brachet, A C Sayag, G Panteix, B Salle, J Bienvenu, V Banssillon, G Burgard, M Manchon.   

Abstract

Intra Peritoneal Chemo Hyperthermia (IPCH) with Mitomycin C (MMC) or Cisplatinum (CP) was used to treat 32 patients with far advanced digestive or ovarian cancers and peritoneal carcinomatosis. Surgical resection of the primary tumor has been possible in 18 cases. After closure of the abdominal wall, a 90 minutes IPCH as performed under general anaesthesia and 32 degrees C general hypothermia, through 3 intraperitoneal drainages realizing a closed circuit, using 10 mg/l of MMC or 15 to 25 mg/l of CP in 6 l of peritoneal dialysate heated at the inflow temperature of 46 to 49 degrees C. The mortality rate was 3% and the morbidity rate was 3%. In 11 out of 12 patients with preoperative malignant ascites, no more ascites could be found after IPCH. For peritoneal carcinomatosis from digestive origin, median survival was 11.2 months and 1 year survival rate was 46.9%. These encouraging preliminary results show that IPCH is a safe and reliable treatment for peritoneal carcinomatosis in far advanced digestive or ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1342062     DOI: 10.1007/bf02987754

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  20 in total

1.  The effects of heat and radiation on cancers implanted on the feet of mice.

Authors:  G CRILE
Journal:  Cancer Res       Date:  1963-03       Impact factor: 12.701

2.  Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors.

Authors:  D Z Chu; N P Lang; C Thompson; P K Osteen; K C Westbrook
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860

3.  Metabolic aspects of the role of hyperthermia im mammalian cell inactivation and their possible relevance to cancer treatment.

Authors:  G M Hahn
Journal:  Cancer Res       Date:  1974-11       Impact factor: 12.701

4.  Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.

Authors:  S Koga; R Hamazoe; M Maeta; N Shimizu; A Murakami; T Wakatsuki
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

5.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.

Authors:  M Torisu; M Katano; Y Kimura; H Itoh; M Takesue
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

6.  Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug.

Authors:  S Koga; R Hamazoe; M Maeta; N Shimizu; H Kanayama; Y Osaki
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

7.  Intra-Peritoneal Chemo-Hyperthermia (CHIP): a new therapy in the treatment of the peritoneal seedings. Preliminary report.

Authors:  F N Gilly; A C Sayag; P Y Carry; G G Braillon; I M James; A A Volloch; G G Panteix
Journal:  Int Surg       Date:  1991 Jul-Sep

8.  Tolerance of intraperitoneal chemohyperthermia with mitomycin C: in vivo study in dogs.

Authors:  F N Gilly; P Y Carry; A C Sayag; G Panteix; M Manchon; A Rochette; J L Peix; J Baulieux; I James; G Braillon
Journal:  Int J Hyperthermia       Date:  1992 Sep-Oct       Impact factor: 3.914

9.  Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer.

Authors:  N Kaibara; R Hamazoe; Y Iitsuka; M Maeta; S Koga
Journal:  Hepatogastroenterology       Date:  1989-04

10.  Prevention of scald injury on the peritoneo-serosal surface in advanced gastric cancer patients treated with intraperitoneal hyperthermic perfusion.

Authors:  S Fujimoto; M Kokubun; R D Shrestha; K Kobayashi; S Kiuchi; C Konno; M Takahashi; K Okui
Journal:  Int J Hyperthermia       Date:  1991 Jul-Aug       Impact factor: 3.914

View more
  4 in total

1.  Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center.

Authors:  Hai-Tao Men; Hong-Feng Gou; Ji-Yan Liu; Qiu Li; DE-Yun Luo; Feng Bi; Meng Qiu
Journal:  Oncol Lett       Date:  2016-04-01       Impact factor: 2.967

2.  Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites.

Authors:  Reese W Randle; Katrina R Swett; Douglas S Swords; Perry Shen; John H Stewart; Edward A Levine; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2013-08-28       Impact factor: 5.344

Review 3.  Treatment of malignant ascites.

Authors:  Michael Chung; Peter Kozuch
Journal:  Curr Treat Options Oncol       Date:  2008-09-06

4.  Cytoreductive surgery and HIPEC for malignant ascites from colorectal cancer - a randomized study.

Authors:  Mingchen Ba; Cheng Chen; Hui Long; Yuanfeng Gong; Yinbin Wu; Kunpeng Lin; Yinuo Tu; Bohuo Zhang; Wanbo Wu
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.